Compare NXP Semiconductors N.V. Common Stock (NXPI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NXP Semiconductors N.V. Common Stock vs Tango Therapeutics Inc. — how do they compare? NXP Semiconductors N.V. Common Stock trades at $220.6 (market cap $57.07B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: NXP Semiconductors N.V. Common Stock is far larger — about 15.2× Tango Therapeutics Inc.'s market cap, and NXP Semiconductors N.V. Common Stock pays a 1.79% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NXP Semiconductors N.V. Common Stock for 5 Days and Tango Therapeutics Inc. for 0 Days on average.
| NXPI | TNGX | |
|---|---|---|
Market Cap | $57.07B | $3.75B |
Volume | 3,033,835 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $332.67 | $32.90 |
52-Week Low | $184.19 | $7.50 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $65.18B | $2.77B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NXP Semiconductors (NXPI) trades at $226.32, up 0.49% with a bearish technical signal despite strong fundamentals. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results expected soon. Revenue grew to $12.27B in 2025 with a robust 22.56% net margin, while analysts maintain a 65% buy rating with a $282.88 consensus target. Recent news highlights executive stock sales and focus on physical AI leadership.
NXPI offers growth potential driven by earnings beats and strategic positioning in semiconductors, but faces near-term technical pressure and competitive risks. The stock trades below analyst targets, suggesting upside if fundamentals hold. Key risks include market volatility and execution challenges in a cyclical industry.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About NXP Semiconductors N.V. Common Stock
NXP Semiconductors designs semiconductor solutions for embedded applications. Its products serve automotive, industrial and IoT, mobile, and communications-infrastructure markets.
Read more on NXPI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
